Abstract: A method of predicting an effect of an anti-c-Met antibody and/or selecting a subject for application of an anti-c-Met antibody including measuring a level of the biomarker in a biological sample, is provided.

Abstract: A method of predicting an effect of an anti-c-Met antibody and/or selecting a subject for application of an anti-c-Met antibody including measuring a level of the biomarker in a biological sample, is provided.

Abstract: Biomarkers for screening drugs reducing side effects of anti-c-Met antibodies and a method of screening using the biomarkers, and more particularly, biomarkers commonly enhancing or reducing gene expression and a method of screening anti-c-Met antibodies having reduced side effects using the biomarkers or a method of screening drugs that reduce side effects of anti-c-Met antibodies.

Abstract: A method and apparatus for analyzing personalized multi-omics data are disclosed. The method includes acquiring a plurality of biological data groups from an individual's gene sample, estimating indices indicating a degree of genetic abnormalities for the biological data groups, and generating a combined index by merging the estimated indices.

Abstract: A method and apparatus for analyzing information about a gene network in which genes included in a genome of an individual are classified into a plurality of subgroups based on functional correlations between the genes is acquired, and subgroups corresponding to an action of at least one drug to be used are visualized.

Abstract: A method and apparatus for analyzing genetic information of abnormal tissue, the method and apparatus involving obtaining a first set of sequence data that includes one or more pieces of sequence data that are aligned in one or more single nucleotide polymorphism (SNP) sites from genetic samples of abnormal tissue; obtaining a second set of sequence data that includes one or more pieces of sequence data that are aligned in one or more SNP sites from genetic samples of normal tissue; analyzing, by a processing unit, a distribution of alleles in corresponding portions of the first set of sequence data and the second set of sequence data; and determining a contamination rate of a sample of a tissue by using a result of the analyzing.

Abstract: A kit and method for predicting cytarabine sensitivity of patients having acute myeloid leukemia are disclosed.

Abstract: In a method and apparatus for detecting positions of data spots on a microarray, images of the microarray are synthesized with a grid-pattern image to distinguish spots on the microarray and synthesized images are thereby generated, and a synthesized image is selected from the synthesized images based on statistics corresponding to light intensities of fiducial spots included in the synthesized images. Accordingly, the positions of the data spots are accurately detected from the selected synthesized image, and the data of the microarray is thereby analyzed.

Abstract: Provided is a substrate that is used to produce a microarray, wherein the substrate includes; a fiducial mark disposed on the substrate, and a probe immobilization region disposed on the substrate, wherein a surface of the first fiducial mark is a hydrophobic and a probe immobilization compound is immobilized on the probe immobilization region.

Abstract: Provided are a method and apparatus for selecting pharmacogenomic markers. The method includes calculating evaluation indexes for evaluating the degree of association between genetic markers of genes associated with at least one drug and the drug, and selecting some of the genetic markers based on the calculated evaluation indexes.

Abstract: Provided are a method and an apparatus for managing data indicating personal genome data. The method includes obtaining property information of a first personal genome data, which indicates genome information of an individual, by analyzing a first personal genome data, and generating integrated data by integrating the first personal genome data and a second personal genome data indicating genome data of the individual based on the obtained property information.

Abstract: Provided is a method of predicting risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, the method including: obtaining a biological sample from a lung cancer patient; measuring an expression level of at least one marker gene from the biological sample, the marker gene being selected from the group consisting of marker genes of Table 1, 2 or 3, to obtain data for the expression level of the marker gene; and determining whether the expression level of the marker gene corresponds to an expression level of a recurrence group or an expression level of a non-recurrence group.

Abstract: Provided is a method of predicting risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, the method including: obtaining a biological sample from a lung cancer patient; measuring an expression level of at least one marker gene from the biological sample, the marker gene being selected from the group consisting of marker genes of Table 1, 2 or 3, to obtain data for the expression level of the marker gene; and determining whether the expression level of the marker gene corresponds to an expression level of a recurrence group or an expression level of a non-recurrence group.

Abstract: Provided is a method of predicting risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, the method including: obtaining a biological sample from a lung cancer patient; measuring an expression level of at least one marker gene from the biological sample, the marker gene being selected from the group consisting of marker genes of Table 1, 2 or 3, to obtain data for the expression level of the marker gene; and determining whether the expression level of the marker gene corresponds to an expression level of a recurrence group or an expression level of a non-recurrence group.